Compare Citius Pharmaceuticals Inc (CTXR) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Huntington Ingalls Industries Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Huntington Ingalls Industries Inc trades at $264.8 (market cap $10.44B). The key difference: Huntington Ingalls Industries Inc is far larger — about 766.5× Citius Pharmaceuticals Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Huntington Ingalls Industries Inc for 28 Days on average.
| CTXR | HII | |
|---|---|---|
Market Cap | $13.62M | $10.44B |
Volume | 132,438 | 440,462 |
Sector | Health | Industrials |
52-Week High | $1.82 | $453.73 |
52-Week Low | $0.48 | $257.05 |
Typical Hold Time | 17 Days | 28 Days |
Enterprise Value | $3.79M | $13.37B |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
HII trades at $265.02, up 1.67% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with a $57.3B backlog, 5.01% net margin, and attractive valuation at P/E 15.78. Recent contract wins including the $5.1B Truman RCOH and 10 ROMULUS USVs provide revenue visibility. Technical indicators show resistance at $268 with support at $261, while moving averages signal bearish pressure.
HII presents a compelling value opportunity with analyst consensus target of $363.67 (37% upside) and 40.74% buy ratings. Strong defense budget tailwinds and contract momentum offset near-term technical weakness. Risks include execution challenges on large contracts and defense spending volatility. The stock offers defensive exposure with dividend yield and consistent earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
